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ABSTRACT
Objectives: To estimate the cost-effectiveness of
remote monitoring strategies versus usual care for
adults recently discharged after a heart failure (HF)
exacerbation.
Design: Decision analysis modelling of cost-
effectiveness using secondary data sources.
Setting: Acute hospitals in the UK.
Patients: Patients recently discharged (within 28 days)
after a HF exacerbation.
Interventions: Structured telephone support (STS)
via human to machine (STS HM) interface, (2) STS via
human to human (STS HH) contact and (3) home
telemonitoring (TM), compared with (4) usual care.
Main outcome measures: The incremental cost per
quality-adjusted life year (QALY) gained by each
strategy compared to the next most effective alternative
and the probability of each strategy being cost-effective
at varying willingness to pay per QALY gained.
Results: TM was the most cost-effective strategy in
the scenario using these base case costs. Compared
with usual care, TM had an estimated incremental cost
effectiveness ratio (ICER) of £11 873/QALY, whereas
STS HH had an ICER of £228 035/QALY against TM.
STS HM was dominated by usual care. Threshold
analysis suggested that the monthly cost of TM has to
be higher than £390 to have an ICER greater than
£20 000/QALY against STS HH. Scenario analyses
performed using higher costs of usual care, higher
costs of STS HH and lower costs of TM do not
substantially change the conclusions.
Conclusions: Cost-effectiveness analyses suggest that
TM was an optimal strategy in most scenarios, but
there is considerable uncertainty in relation to clear
descriptions of the interventions and robust estimation
of costs.
BACKGROUND
Heart failure (HF) is associated with high
levels of morbidity and mortality, with the
highest risk being immediately after
discharge from hospital.1 A total of 20–30%
of patients are readmitted within 30 days,
rising to 50% at 6 months.2 Patients who are
discharged have around 28% risk of mortal-
ity within the ﬁrst year after HF discharge.3
Strategies to slow disease progression are
needed for at-risk patients, to improve the
prognosis, even among those receiving
optimal pharmaceutical therapy.4
Remote monitoring (RM) of indicators of
deterioration (eg, weight, arrhythmia, blood
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pressure, intrathoracic impedance, heart rates during
rest and exertion and symptom control) can facilitate
early detection of clinically signiﬁcant changes as well as
earlier intervention to restabilise the syndrome, prevent
emergency admissions and avoid complications.5 RM
can be broadly classiﬁed into telemonitoring (TM), in
which physiological data are electronically transmitted to
a healthcare team, and structured telephone support
(STS), that is, the use of phone calls, usually by specialist
nurses, to deliver self-care support and/or manage-
ment.6 For STS, support can be provided by human-to-
human contact (HH), or via a human-to-machine inter-
face (HM); that is, STS with an interactive response
system (eg, a voice-interactive system). For TM, support
can be provided during ofﬁce hours only or 24 h/ day,
7 days/week (24/7), though few studies have used the
latter approach.
The cost-effectiveness of an RM strategy can be esti-
mated by comparing the outcomes and costs associated
with the strategy to the next most effective alternative. If
these outcomes are estimated as quality-adjusted life
years (QALYs), then the incremental cost-effectiveness
ratio (ICER), or cost per QALY gained, can be calcu-
lated and compared to alternative uses of healthcare
funding. In the UK (UK), the National Institute for
Health and Clinical Excellence (NICE) typically recom-
mends in favour of funding interventions with an ICER
below thresholds of £20 000/QALY, requires consider-
able clinical beneﬁt to recommend funding interven-
tions between £20 000 and £30 000/QALY, and
recommends against funding interventions with an
ICER above these thresholds. The aim of this paper is to
estimate the incremental cost per QALY of RM strategies
compared with usual care, so as to determine which RM
strategy should be recommended according to typical
NICE thresholds for cost-effectiveness.
METHODS
Model scope
A Markov model was developed using MS Excel software
(Microsoft Corporation) to estimate the cost-effectiveness
of RM interventions with usual care for patients dis-
charged in the past 28 days with a HF-related hospital-
isation,7 measured as the incremental cost per QALY
gained by each strategy compared with the next most
effective alternative on the cost-effectiveness frontier.
Cost-effectiveness results are estimated as mean values of
10 000 probabilistic sensitivity analysis (PSA) runs, with
each PSA run using different estimates for the risks, HRs,
costs and utilities sampled from probability distributions
representing uncertainty in the parameter estimates.
Additionally, the probability that each strategy would be
the most cost-effective was calculated at different thresh-
olds for willingness to pay (WTP) for health gain.
Cost-effectiveness acceptability curves were constructed
by plotting the probability of each strategy being cost-
effective against the WTP threshold.
The following strategies postdischarge interventions
were tested in the model:
A. Usual care
B. STS HH (structured telephone support with
human-to-human contact)
C. STS HM (structured telephone support with
human-to-machine interface) and
D. TM (ie, telemonitoring with transmitted data
reviewed by medical staff or medical support pro-
vided during ofﬁce hours)
The clinical effectiveness parameters of these three
RM strategies were estimated from a network
meta-analysis of the available evidence,8 and costs were
estimated using ‘bottom up’ costing methods. It was
assumed that the interventions were provided for the
6 months following discharge from the hospital, as the
majority of the RM trials included in the network
meta-analysis used a 6-month follow-up duration.8 At the
end of 6 months, all patients were assumed to receive
usual care as per the NICE Clinical Guidelines for the
Management of Adults with Chronic Heart Failure,9 irre-
spective of whether they received intervention or post-
discharge usual care during the treatment period.
Model structure
In the Markov model, two different states were
considered:
A. Alive at home
B. Dead
The Markov model used a monthly cycle length with
half-cycle correction and assigned each patient with a
monthly probability of death based on the time since
discharge and the type of treatment. In each period, the
patients who were alive were under the risk of an
average number of monthly rehospitalisations, that is,
readmissions to a hospital for HF or other causes. Each
patient then accrued lifetime QALYs and healthcare
costs according to their hospitalisation and treatment
status. The model used a 30 year (patient lifetime)
horizon, although the impact of each intervention was
for the ﬁrst 6 months after an initial discharge. The
costs and QALYs were discounted at an annual discount
rate of 3.5% and the economic perspective of the model
was that of the NHS in England and Wales. Repeat inter-
ventions after repeat hospitalisations were not consid-
ered in this model.
Baseline mortality and hospitalisation
The baseline monthly probabilities of death were esti-
mated from Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity (CHARM) study,10
which included 7572 patients with a mean age of
65.5 years followed up for 38 months, as it assessed the
inﬂuence of non-fatal hospitalisation for heart failure on
subsequent mortality. The data from the CHARM
study10 showed that the mortality risk was highest imme-
diately after hospital discharge and then decreased over
time, as shown in table 1.
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The mean numbers of HF-related and other-cause
hospitalisations (estimated as all-cause hospitalisations
minus the HF-related hospitalisations) were estimated
from a meta-analysis of 21 studies (5715 patients,
median age 70.7 ranging from 45 to 78 years) reported
by Klersy et al.11 The average number of monthly
HF-related and all cause rehospitalisations for patients
in usual care are as shown in table 2.
Effectiveness of interventions
The effectiveness parameters in the economic model were
the HRs for all-cause mortality, all-cause hospitalisations
and HF-related hospitalisations for the different interven-
tions (ie, STS HM, STS HM and TM) against standard
care. These effectiveness parameters were estimated from
a network meta-analysis (NMA) of 21 RM studies8 (total
6317 patients, with the mean age across studies ranging
from 57 to 78 years) and applied to the baseline para-
meters to estimate the hospitalisation and mortality risk
parameters for the different interventions. It was assumed
that the treatment effectiveness (and costs) lasts only for
the treatment duration of 6 months, after which the base-
line risks of hospitalisation and mortality are applied.
It should be noted that considerable heterogeneity
was identiﬁed in the manner in which RM and usual
care were performed among the studies included in
NMA,8 which resulted in heterogeneity between studies
in the estimate of HRs. For example, in RM, there was
variation between studies in the type of devices used,
parameters monitored and the protocols for triage and
follow-up. In particular, the data from Dar et al12
(Home-HF trial conducted in three district general hos-
pitals in West London) appeared to be inconsistent with
the data from the remaining studies because it showed a
higher incidence of mortality among the TM group
than the usual care group. However, the 6-month
mortality rate in the usual care group (5.5%) was sub-
stantially lower than would be expected in a HF cohort
receiving care outside the context of a clinical trial (ie,
between 13% and 21%),3 which the authors attributed
to the high-quality usual care (provided by a HF nurse
specialist and a consultant with an interest in HF). The
impact of this study was assessed in sensitivity analyses,
and HRs from both the NMAs are presented in table 3.
On deciding which of these results are most representa-
tive of their setting, the key question for decision-makers
relate to the inclusion of the Home-HF study12 in the
effectiveness meta-analyses. If one accepts that usual care
is best represented by the usual care arm in the Home-HF
study,12 which is the only study showing a statistically signiﬁ-
cant difference in effectiveness of usual care over RM,
then the results including Home-HF study12 might be con-
sidered more relevant than those without. If, on the other
hand, one considers that the performance of usual care is
better represented by the other studies and that usual care
in Home-HF study12 is not representative of current usual
care, then the results excluding Home-HF study12 might
be more generalisable. This consideration predominantly
affects the HRs around the telemonitoring intervention
only and does not impact substantially on the structure
telephone service interventions.
Health-related quality of life
A review was conducted to estimate the health-related
quality of life (HRQoL) and four studies were found,13–
16 all of which reported utilities for recently discharged
HF patients under usual care around 0.57 to 0.6. There
was no quantiﬁed evidence on the extent to which RM
improves the HRQoL of the patients in the RM studies
included in NMA, and thus the same utility values were
used for HF patients in usual care as well as (each of the
three) RM strategies in the economic model. The disutil-
ity caused by rehospitalisation for HF was estimated as
0.1 based on a study by Yao et al17 who estimated the dis-
utility to be equivalent to the utility of one health state
lower in terms of the New York Heart Association
(NYHA) class, and this disutility was assumed to last for
1 year. In the absence of evidence regarding the disutil-
ity caused by rehospitalisation for other causes (not dir-
ectly HF-related), it was assumed that there was no
disutility caused by rehospitalisation for other causes.
A utility score of 0.58 was applied to the patients for
each month in the ﬁrst year after discharge and a utility
score of 0.67 was used after the ﬁrst year. Any HF-related
hospitalisation was assumed to result in a disutility of 0.1
for a whole year, that is, the utility of the patient for that
Table 2 Monthly risk of hospitalisations per patient in usual care
Source Estimate Lower 95% CI Upper 95% CI
HF-related hospitalisations Klersy et al11 0.0350 0.0325 0.0375
All-cause hospitalisations Klersy et al11 0.0875 0.0841 0.0908
Table 1 Monthly mortality probability vs time since
discharge for patients with heart failure (HF) in usual care
Time since
discharge
(in months)
Mortality
probability
per month
Lower
95% CI
Upper
95% CI
0–1 0.04622 0.03616 0.05891
1–3 0.03306 0.02644 0.04124
3–6 0.02674 0.02166 0.03306
6–12 0.02353 0.01964 0.02831
12–24 0.01866 0.01565 0.02226
>24 0.01467 0.01127 0.01911
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year was 0.67–0.1, that is, 0.57. Within the PSA, the
uncertainty in the utility values was represented using a
normal distribution using the deterministic values as the
mean with an SD of 0.015 and estimated based on the
difference between the utilities reported by Capomolla
et al13 and Iqbal et al,15 while the disutility was repre-
sented using a triangular distribution with (−0.08, 0.11)
as the range with −0.1 as the mode.
Costs
The costs used in the model are (1) costs of RM inter-
ventions after initial discharge only, (2) costs of usual
care and (3) repeat hospitalisation costs. These costs are
summarised in table 4 and are described in detail in this
section.
The RM studies did not report clearly or in detail
what was involved in the usual postdischarge care or
RM, thus making it difﬁcult to accurately determine the
costs.8 Owing to the variation involved in the RM inter-
ventions and usual care, cost scenarios were developed
for each RM classiﬁcation (ie, STS HM, STS HH and
TM) and usual care. These costs were estimated using
bottom-up costing methods for a typical health organisa-
tion of 250 HF patients (estimated based on the median
size of the NHS Foundation Trusts in the UK) for a
period of 6 months. Furthermore, it was assumed that,
after 6 months, all patients would receive usual care as
recommended in NICE clinical guidelines for the man-
agement of adults with CHF,9 irrespective of whether
they received the remote monitoring intervention or
postdischarge usual care during the intervention period.
It was assumed that the usual postdischarge care was
the same as that described in the TEN-HMS study18 and
the usual care costs were estimated by applying the
hourly NHS staff rates from PSSRU 201119 to the
resource use data in the TEN-HMS study.18 A high cost
usual postdischarge care scenario was also developed
based on discussions with the clinical expert group (AB,
AAM, JC and MRC).
The total costs of RM interventions were broken down
into the costs of the device, monitoring costs and
medical care costs.8 The costs of the RM devices were
elicited from an expert advisory group. The monitoring
costs were estimated using activity-based costing for the
Table 4 Cost parameters used in the economic model
Costs (in £) per 6 months
Base-case
scenario
Low-cost
scenario
High-cost
scenario Source
UC £161 – £592 TEN-HMS,18 Clinical opinion
STS HM £715 £623 £794 Clinical opinion
STS HH £1075 £1051 £1152 Clinical opinion
TM £1051 £801 £1288 Clinical opinion
Usual care costs (per month) after 6 month intervention duration
UC after 6 months £8.23 – – NICE HF guidelines9
Hospitalisation costs Estimate Lower 95% CI Upper 95% CI
HF-related hospitalisations* £2514.49 £1857 £2809 NHS Reference Costs for
201121
Other-cause hospitalisations† £1529.79 £1129 £1709 NHS Reference Costs for
201121
*Heart failure or shock (EB03H EB03I): non-elective inpatient (long stay) including excess bed days.21
†Non-elective inpatient (long stay and short stay) including excess bed days.21
Table 3 HRs for interventions versus usual care for all-cause mortality and hospitalisations
HRs for interventions versus usual care for mortality (all-cause) and hospitalisation (all-cause and HF) from NMA
including Home-HF12 study
Type
All-cause mortality HF-hospitalisation All-cause hospitalisation
R 95% PrI HR 95% PrI HR 95% PrI
STS HH 0.77 (0.31, 1.86) 0.77 (0.50, 1.19) 0.97 (0.38, 2.43)
STS HM 0.98 (0.30, 3.23) 1.03 (0.58, 1.77) 1.06 (0.31, 3.61)
TM 0.76 (0.30, 1.91) 0.95 (0.59, 1.62) 0.75 (0.28, 1.91)
HRs for interventions versus usual care for mortality (all-cause) and hospitalisation (all-cause and HF) from NMA
excluding Home-HF12 study
STS HH 0.75 (0.45, 1.27) 0.76 (0.51, 1.13) 0.96 (0.42, 2.18)
STS HM 0.98 (0.49, 1.95) 1.02 (0.61, 1.69) 1.06 (0.35, 3.22)
TM 0.62 (0.35, 1.09) 0.86 (0.54, 1.38) 0.67 (0.26, 1.53)
HR, hazard ratio; PrI, predictive interval; STS HM, structured telephone support via human to machine interface; STS HH, structured
telephone support via human to human contact; TM, telemonitoring
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resources spent by the staff on triage and follow-up
based on evidence from the literature.20 The costs of
medical care for the usual care arm, STS and TM arms
were estimated by applying the hourly NHS staff rates
from PSSRU 201119 to their respective medical care
resource use data reported in the TEN-HMS study.18
The mean inpatient admission cost for HF-related hos-
pitalisations was calculated from the weighted average of
the costs for the HRG ‘Heart Failure or Shock” (EB03H,
EB03I) based on the data obtained from the NHS
Reference Costs for 2011.21 For hospital admissions for
any cause other than HF, it was assumed that these costs
were the same as the mean cost of hospital admission
for the general population. This was estimated as a
weighted average of elective inpatient admissions and
non-elective inpatient admissions (including short and
long stay) based on the data from the NHS Reference
Costs for 2011.21
RESULTS
The results of the cost-effectiveness analysis using base
case costs are presented in table 5 for both estimates of
effectiveness, including and excluding data from the
Home-HF study,12 to address the uncertainty in
the effectiveness evidence. Results are also presented for
ﬁve cost scenarios (higher usual care cost scenario,
lower cost scenario of TM, higher cost scenario of TM,
lower STS cost scenario and higher STS cost scenario)
and the 12 month intervention duration scenario in
online supplementary tables S1 and S2, respectively.
In the analysis using base case costs, TM is the most
cost-effective strategy at a threshold of £20 000/QALY in
both analyses, that is, including and excluding the
Home-HF study.12 TM is also the most effective strategy
(ie, highest QALYs gained) in the analyses that excluded
the Home-HF study,12 but not in the analyses that
included the Home-HF study,12 with STS HH providing
the highest number of expected QALYs. However, the
additional QALYs gained by STS HH are not worth the
additional costs of the strategy as seen in the ICERs
(against TM) greater than the threshold of £20 000/
QALY.
In the analyses that included the Home-HF study,12
there is only a 40% chance of TM being cost-effective at
the threshold of £20 000/QALY, as shown in ﬁgure 1.
Excluding the Home-HF study,12 the probability that TM
during ofﬁce hours is cost-effective increases to 73%
(ﬁgure 2).
Scenario analyses performed using higher costs of
usual care, higher costs of STS HH and lower costs of
TM do not substantially change the conclusions. TM was
estimated to be the most cost-effective strategy in all
these scenarios. Scenario analysis performed using
higher costs of TM (£215/month) suggested that TM is
dominated by STS HH. This is because a small change
in the difference between costs of TM and STS HH led
to a marked change in ICERs, given the small difference
(0.0021 QALYs) in expected QALYs between STS HH
and TM in the analyses that included the Home-HF
study.12 However, the same scenario analysis (ie, higher
cost of TM of £215/month) that excluded the data from
the Home-HF study12 suggested that TM is still the most
cost-effective strategy with an ICER of £8223/QALY
against usual care (STS HH is extendedly dominated by
a combination of usual care and TM). This is due to the
much higher difference in the expected QALYs between
STS HH and TM (0.0602 QALYs), where a small change
in the difference between costs of TM and STS HH
cannot lead to a marked change in the ICER. The
threshold analysis suggested that the monthly cost of TM
has to be higher than £390/month to have an ICER
greater than £20 000/QALY against STS HH. The ICER
of TM against usual care, at this monthly cost of £390, is
£13 357/QALY.
Scenario analyses performed using different estimates
of the disutility for HF-related and other cause hospitali-
sations produced results similar to that in the base case
Table 5 Summary of the economic analysis results using base case costs
Usual care STS HM STS HH TM
Total costs
Including Home-HF12 £8478 £8965 £9574 £9437
Excluding Home-HF12 £8478 £9087 £9658 £9665
Total QALYs
Including Home-HF12 2.4137 2.3633 2.4950 2.4944
Excluding Home-HF12 2.4137 2.4043 2.5230 2.5847
ICERs
Including Home-HF12 Dominated £228 035* £11 873
Excluding Home-HF12 Dominated Extendedly dominated £6942*
Probability of cost-effectiveness (%)
Including Home-HF12 6 19 35 40
Excluding Home-HF12 1 7 19 73
*Last strategy in the cost-effectiveness frontier.
ICERs, incremental cost-effectiveness ratios; QALYs, quality adjusted life years; STS HH, structured telephone support via human to human
contact; STS HM, structured telephone support via human to machine interface; TM, telemonitoring.
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analysis, that is, the results are robust to the variations in
the disutility of hospitalisations.
Scenario analysis using a 12-month treatment duration
produced similar results as in the 6-month treatment
duration scenarios. TM for 12 months was also cost-
effective when compared with TM for 6 months with an
ICER of £14 066/QALY. However, treating 2×N patients
using TM for 6 months was cost-effective with it being
dominant against a combination of treating N patients
using TM for 12 months with the rest of the N patients
under usual care.
DISCUSSION
The results of the base case cost-effectiveness analyses
suggest that TM is expected to be the most cost-effective
strategy at a threshold of £20 000/QALY. However, there
is uncertainty involved in suggesting that TM is the most
probable cost-effective strategy and. in particular, there
is greater uncertainty when data from the Home-HF
study12 is included than when it is excluded. For
decision-makers, the key question is whether the usual
care arm in their local setting is similar to the usual care
arm in the Home-HF study.12 If so, then the results
including the Home-HF study12 might be considered
more relevant and if not, the results excluding the
Home-HF study12 might be considered more relevant.
The scenario analysis performed (using higher usual
care costs, lower TM costs, higher TM costs and higher
STS costs) did not substantially change the conclusions.
TM was estimated to be the most cost-effective strategy
in all these scenarios. Furthermore, TM for 12 months
was also cost-effective when compared with TM for
6 months, which suggests that it is cost-effective to keep
the patients on TM beyond 6 months. In situations with
a limited number of TM devices, assuming a homoge-
neous patient group, it is cost-effective to treat all
patients using TM for 6 months than using TM for
12 months on half the patients with the other half of the
patients under usual care.
There have been two cost-effectiveness analyses studies
of RM in HF, but neither considered the different RM
Figure 1 Cost effectiveness
acceptability curve for base case
economic analysis using
effectiveness data including the
Home-HF study.12
Figure 2 Cost effectiveness
acceptability curve for economic
analysis using effectiveness data
excluding the Home-HF study.12
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approaches separately.11 22 The analysis reported by
Miller et al22 was based on a single trial of STS,23
whereas Klersy et al11 included data from a meta-analysis
of a wide range of RM studies. Miller et al22 estimated
that STS compared with usual care had an ICER around
$43 650/QALY; this study did not include a PSA, but
univariate sensitivity analyses (ICER varying from
$28 691 to $129 738 per QALY) was performed. Klersy
et al11 focused mainly on the effectiveness rather than
the costs and used a time horizon of 1 year. A budget
impact analysis was presented and the different
diagnosis-related group (DRG) reimbursement tariff
groups, as a proxy for hospitalisation costs, were consid-
ered with cost savings per patient ranging between
€306.8 and €992.94. However, other costs such as RM
costs and outpatient visit costs were not considered. The
authors performed scenario analyses using different
DRG costs as part of the budget analysis to address the
uncertainty in the hospitalisation costs, but neither
deterministic sensitivity analysis nor PSA was performed.
The Whole systems demonstrator (WSD) pro-
gramme,24 a randomised controlled trial of telehealth
that included over 6000 patients, analysed costs and out-
comes for 965 patients monitored for 12 months: 534
receiving telehealth and 431 receiving usual care.
Cost-effectiveness analysis estimated the ICER at
£92 000/QALY when telehealth was added to usual care
for people with chronic conditions (diabetes, HF and
chronic obstructive pulmonary disease (COPD)).
However, this trial-based evaluation (with a time horizon
of 1 year) potentially underestimates the health beneﬁts
as it does not include the long-term QALYs gained from
the reduction in mortality. Furthermore, the WSD ana-
lysis included all patients with chronic conditions (dia-
betes, HF and COPD), whereas the population under
consideration in our analysis included patients who had
been recently discharged with HF. The cost-effectiveness
results for HF patients are not yet publicly available in a
peer-reviewed journal, and thus it is difﬁcult to compare
the results of the current analysis with the results of the
WSD analysis.
The analysis reported in this paper also has some lim-
itations that need to be taken into account. Any model-
ling process involves simpliﬁcations and assumptions
that may not accurately reﬂect clinical practice. Owing
to the lack of detail provided in research studies
included in the NMA concerning the components of
RM packages and usual care (eg, communication proto-
cols, routine staff visits and resources used), scenarios
for different RM classiﬁcations were developed and their
costs were estimated using bottom-up costing methods.
Although the users can decide which of these analyses is
most representative of their setting, uncertainties still
remain about the assumptions made in the estimation of
these costs. However, it should be noted that the
monthly costs estimated were similar to those reported
in the WSD. Implementation costs (such as set-up costs,
staff training costs, service reconﬁguration costs, costs
for dual running of usual care and RM services) were
not included in the model but are often a consideration
for the health organisations.
RM interventions included in the NMA were heteroge-
neous in terms of monitored parameters and selection
criteria for HF; this was the case even within speciﬁc
types of RM (STS HH, STS HM and TM) and is
reﬂected in the uncertainty of the effectiveness para-
meters. A limitation of the analyses is that the effective-
ness parameters remained the same for the different
cost scenarios, whereas in reality there might be some
correlation between the costs and effectiveness of differ-
ent RM strategies. Also, it was assumed that the effective-
ness and costs of the interventions are constant over
time, irrespective of the duration of deployment.
Furthermore, as the analysis is not severity speciﬁc, it
assumes that the interventions are equally effective in
different severity groups within the population under
consideration (ie, patients who are recently discharged
with HF). Repeat interventions after repeat hospital
admissions for heart failure are not modelled and the
mortality risk is not reset for patients who are readmit-
ted as this would need detailed evidence on baseline
risks and effectiveness in different patient groups. As this
detailed evidence is not available, the cohort model uses
evidence about the overall average of the patients to esti-
mate the cost-effectiveness.
Some of the assumptions above may not hold true in
reality, and therefore further research is needed to address
these issues. Given the complex nature of RM interven-
tions, new research should seek to examine the ‘active
ingredients’ of RM and identify patient subgroups that can
beneﬁt most from the intervention, as well as patients in
whom these interventions are unlikely to be effective. In
addition, usual care ought to be more robustly deter-
mined, reﬂecting best practice as deﬁned in the current
guidelines, although this is not commonly the case.
Furthermore, to aid robust cost-effectiveness estimations,
the costs associated with usual care and RM interventions
need to be reported in detail (including the costs of HF
treatment pathways) and QoL needs to be reported with
observations at speciﬁc time points in order to estimate
the difference in the utility of the patients between the
RM and usual care groups. Future studies should provide
greater detail on reconﬁguration and set-up costs and link
more clearly with the ﬁnancial impact (eg, cost variation
with scale and over time) on provider organisations. Wider
adaptation of RM in the NHS can be facilitated by provid-
ing ﬁnancial impact data (eg, set-up costs, quarterly costs
of service, costs of reconﬁguration) along with the long-
term cost-effectiveness information.
The results of the current analysis have important
implications for the healthcare systems facing rising
demand from emergency admissions. HF is a leading
cause of hospitalisation in the UK, with 58 164 admis-
sions recorded for HF (as ﬁrst diagnoses) between April
2009 and March 2010 in England and Wales.25 The cost
of inpatient bed days for HF alone has been estimated at
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£563 million,26 with around 90% of HF admissions to
emergency departments,27 lasting a median of 9 days.25
The evidence shows that use of RM could substantially
reduce HF admissions, with an associated reduction in
pressure on acute beds, and consequent cost savings.
Furthermore, the use of TM might allow the potential
transfer from emergency admission to elective admis-
sion, that is, scheduling admissions of patients directly
(not via A&E) to either a ward or to a day unit for off-
loading, leading to major resource savings, with less
patient disutility.
Indeed, the Department of Health (DH) recognised
this potential and launched an initiative, ‘3 Million
Lives” (3ML), to help at least three million people
with long-term conditions and/or social care to
beneﬁt from the use of telehealth and telecare ser-
vices.28 A concordat has been entered into by the DH
and the telehealth and telecare industry to work
together to accelerate the use of TM.29 Thus far, seven
pathﬁnder sites have agreed contracts with the indus-
try to ensure that 100 000 people beneﬁt from the
technology in 2013.30 Implemented effectively as part
of a whole system redesign of care, TM may alleviate
the pressure on long-term NHS costs and improve
people’s quality of life through better self-care in the
home setting.
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